

Efficacy and Safety of Gefitinib Plus Pemetrexed/Platinum in Advanced EGFR-Mutated Lung Adenocarcinoma Patients: A Real-World Observational Study [Retraction]Wang R, Wu Q. *Onco Targets Ther.* 2022;15:31–39.

At the authors request, the Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. The authors contacted the journal to advise that several actions reported in the article were not performed and some of the data had been falsified. Specifically, the retrospective collection and analysis of data from 30 advanced lung adenocarcinoma patients with EGFR mutations described in the Control Cohort section on page 32 did not occur.

The authors wish to apologise for their actions and the inconvenience this has caused.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

<https://doi.org/10.2147/OTT.S394058>